An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has announced the acceptance of a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. The presentation will be given by Dr. Monica Moreno on December 10, 2023, from 6:00 - 8:00 p.m. PDT.
Positive
None.
Negative
None.
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.
Details of the poster presentation are as follows:
Title: Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
Poster Number: 3478
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Presenting Author: Monica Moreno, Ph.D.
Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
What is the company name mentioned in the press release?
The company mentioned in the press release is Adicet Bio, Inc.
What is the ticker symbol of Adicet Bio, Inc.?
The ticker symbol of Adicet Bio, Inc. is ACET.
What is the focus of Adicet Bio, Inc.?
Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer.
What is the upcoming event mentioned in the press release?
The upcoming event mentioned in the press release is the 65th American Society of Hematology (ASH) Annual Meeting.
What will be the topic of the poster presentation?
The topic of the poster presentation will be the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.
Who will be the presenting author of the poster presentation?
The presenting author of the poster presentation will be Dr. Monica Moreno, Ph.D.
When and where will the poster presentation take place?
The poster presentation will take place on Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
